ライフサイエンスコーパス: QALY

1 QALYs were generated from overall survival and patients'

2 py was the preferred strategy ($35,560; 14.0 QALYs).

3 below the range of Can$20 000 to Can$100 000/QALY and below US$50 000/QALY, thresholds generally used

4 cost-effectiveness ratios less than $100,000/QALY considered cost effective.

5 hreshold and 65% of iterations at a $100,000/QALY threshold.

6 t a willingness-to-pay threshold of $100,000/QALY.

7 US willingness-to-pay threshold of $150 000/QALY saved.

8 Achieving these benefits costs $253 000/QALY gained.

9 000 to Can$100 000/QALY and below US$50 000/QALY, thresholds generally used to evaluate the cost-eff

10 ncremental cost-effectiveness ratio <$50,000/QALY gained.

11 -effective in 70% of iterations at a $50,000/QALY threshold and 65% of iterations at a $100,000/QALY

12 QALY for induction-maintenance and >$500 000/QALY for standard of care.

13 sfunction (all with ICERs $50,000 to $70,000/QALY gained), patients age <75 years (ICER = $44,779/QAL

14 At a pound30,000/QALY willingness-to-pay threshold and current prevalence

15 S willingness-to-pay threshold ( pound30,000/QALY).

16 0 [range pound35,300-61,400] and pound48,000/QALY [ pound34,600-74,800], respectively) and, in specia

17 years, respectively, standard error = 0.005 QALY), at increasing average costs: US$3445 (annual moni

18 Can$1508, discounted) and 48.93 QALYs (16.09 QALYs, discounted).

19 n effectiveness was 0.04 (95% CI, 0.02-0.09) QALY at $883 above usual care.

20 d with the physician-based model (i.e., 13.1 QALYs).

21 be Can$5530 (Can$4512, discounted) and 50.12 QALYs (16.42 QALYs, discounted).

22 similar to the fixed 12-month policy (6.135 QALYs, US$3518).

23 horseshoe tear resulted in $2981/QALY ($1436/QALY).

24 ing effect, the ICER decreased to euro10 149/QALY ($11 163/QALY).

25 e ICER decreased to euro10 149/QALY ($11 163/QALY).

26 ost-effective ($353/QALY [95% CI, $244-$1769/QALY) moisturizer in the cohort.

27 ut was also less effective (-0.1814, -0.1831 QALY, respectively).

28 pproach, yielding an additional NHB of 0.198 QALY compared with the standard biopsy approach.

29 fter 3 years, surgery led to a gain of 0.199 QALYs compared with no surgery at an incremental cost of

30 osts, but the cost-utility increases to 0.21 QALY per patient.

31 history of RD resulted in $4414/QALY ($2187/QALY).

32 were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively.

33 QALY saved was $255 to $638/QALY ($100-$239/QALY).

34 symptomatic horseshoe tear resulted in $2981/QALY ($1436/QALY).

35 hly cost-effective ($27 863/QALY and $19 302/QALY, respectively) relative to status quo and at a US w

36 Petrolatum was the most cost-effective ($353/QALY [95% CI, $244-$1769/QALY) moisturizer in the cohort

37 to F3 patients were $30,484/QALY and $25,367/QALY, respectively.

38 -year effect of CXL, the ICER was euro54 384/QALY ($59 822/QALY).

39 ce between the mean QALYs was 4.7 days (46.4 QALY days for the OSC plus WBRT group vs 41.7 QALY days

40 to 2012 US dollars were US $342,799 and 5.42 QALY, yielding US $63,775 per QALY gained.

41 by $6,000 and improved effectiveness by 0.42 QALYs compared with primary surgery alone.

42 Can$4512, discounted) and 50.12 QALYs (16.42 QALYs, discounted).

43 th peripheral artery disease (ICER = $13,427/QALY gained).

44 ow eye had a history of RD resulted in $4414/QALY ($2187/QALY).

45 the intervention was still less than $45000/QALY.

46 gery or ILI only to F3 patients were $30,484/QALY and $25,367/QALY, respectively.

47 sts, while intensive management yielded 10.5 QALYs and accrued $176584 in costs.

48 The ICER was $22 500/QALY for induction-maintenance and >$500 000/QALY for st

49 RFA-SBRT yielded 1.558 QALYs and cost $193 288.

50 Results: Standard management yielded 9.6 QALYs and accrued $155261 in lifetime costs, while inten

51 ,006 chronic HBV infections and saved 13,600 QALYs (ICER: $6,957/QALY saved).

52 of cost-effectiveness; mean ICER pound62,600/QALY [ pound48,000-89,400]).

53 n additional 1.81 life-years gained, or 0.62 QALYs, at a cost of $472,668 per QALY gained.

54 The cost per QALY saved was $255 to $638/QALY ($100-$239/QALY).

55 ALY days for the OSC plus WBRT group vs 41.7 QALY days for the OSC group), with two-sided 90% CI of -

56 idered non-inferior if it was no more than 7 QALY days worse than treatment with WBRT plus OSC, which

57 ss than 8 h, inexpensive with a ICER of $8.7/QALY, and affordable in developing countries and area wh

58 ER obtained using policy 1 was euro19,541.75/QALY.

59 e ICER obtained using policy 1 was euro8,775/QALY.

60 ned), patients age <75 years (ICER = $44,779/QALY gained), and patients with peripheral artery diseas

61 ional 489 chronic infections, and saving 800 QALYs and $2.8 million.

62 f CXL, the ICER was euro54 384/QALY ($59 822/QALY).

63 ld, moderate, or severe obesity were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively.

64 ence, and are highly cost-effective ($27 863/QALY and $19 302/QALY, respectively) relative to status

65 emental cost effectiveness ratio of $198,867/QALY.

66 remental cost effectiveness ratio of $90,871/QALY, and first-line NIVO + IPI followed by carboplatin

67 Our ICER of Can$9090/QALY falls well below the range of Can$20 000 to Can$100

68 CXL to conventional management was Can$9090/QALY gained.

69 l cost-effectiveness ratio (ICER) of $94,917/QALY gained.

70 re Can$2675 (Can$1508, discounted) and 48.93 QALYs (16.09 QALYs, discounted).

71 or severe obesity were $48,836/QALY, $24,949/QALY, and $19,222/QALY, respectively.

72 ections and saved 13,600 QALYs (ICER: $6,957/QALY saved).

73 2 +/- 212.15 for the anti-VEGF group, with a QALY gain of 0.21, the yearly mean cost was euro7153.62

74 to the highest NHB gain of 0.251 additional QALY compared with the standard biopsy strategy.

75 , 0.69 additional life-year, 0.62 additional QALY, and $29 203 in incremental costs, equating to a co

76 frameworks) and criterion validity (against QALYs from the National Institute for Health and Care Ex

77 ect medical expenditure, and cost per LY and QALY gained.

78 Cost and QALYs were used to calculate an incremental cost-effecti

79 Lifetime costs and QALYs for conventional management with PKP were Can$2675

80 Lifetime costs and QALYs for CXL were estimated to be Can$5530 (Can$4512, d

81 The incremental costs and QALYs gained with sacubitril/valsartan treatment were es

82 iscounted at 5%, converting future costs and QALYs into present values.

83 Costs and QALYs were discounted at 5%, converting future costs and

84 Project ECHO increased costs and QALYs.

85 r low-income contexts achieved 6.142 average QALYs at a cost of US$3524, similar to the fixed 12-mont

86 her strategies were dominated (greater costs/QALY gained than more effective strategies).

87 a probability of 84% to 98% that cumulative QALYs were higher and a probability of 91% to 99% that c

88 oup had a probability of 96% that cumulative QALYs were higher and cumulative costs were lower than i

89 EP), and lead to a gain of 40 000 discounted QALYs over an 80-year time horizon.

90 1.01, 95% CI 0.86-1.19; p=0.95) or economic (QALY: mean difference 0.006, -0.009 to 0.02; p=0.42) out

91 nal Institute for Health and Care Excellence QALY threshold of pound20 000.

92 -income resource settings yields 0.008 fewer QALYs per person, but saves US$204 compared to monitorin

93 associated with increased cost and improved QALY: incremental cost, $105398; incremental QALY, 0.39,

94 ould result in increases as follows: 0.77 in QALY per patient with any-DR and 0.6 and 0.44 per patien

95 , the combination of the small difference in QALYs and the absence of a difference in survival and qu

96 st-effective based on a modest difference in QALYs between groups.

97 The difference in QALYs gained between the test and no test options was 47

98 Both screening strategies produced a gain in QALYs, resulting in incremental cost-effectiveness ratio

99 oth a net cost savings and a net increase in QALYs.

100 and 55.4% when effectiveness was measured in QALYs for total costs and 31.3% and 34.3%, respectively,

101 ative care- 1,169,121 Thai baht) and more in QALYs (peg 2a- 13.44 vs. peg 2b- 13.14 vs. palliative ca

102 l costs by euro592 per patient and increased QALYs by 0.034 per patient.

103 ILI in obese patients (with F0-F3) increased QALYs by 0.678-2.152 and 0.452-0.618, respectively, comp

104 eased QALYs by 0.050-0.824 and ILI increased QALYs by 0.031-0.164.

105 is study, AIMS reduced viral load, increased QALYs, and saved resources.

106 ght patients (with F0-F3), surgery increased QALYs by 0.050-0.824 and ILI increased QALYs by 0.031-0.

107 e; in overweight patients, surgery increased QALYs for all patients regardless of fibrosis stage, but

108 nt thresholds were associated with increased QALYs (0.002-0.004), and only quadrennial screening of p

109 ll strategies were associated with increased QALYs (0.002-0.004), and several strategies were potenti

110 ant over the old policy because it increases QALYs at lower cost.

111 QALY: incremental cost, $105398; incremental QALY, 0.39, with an ICER of $268637 per QALY gained ($16

112 6-month time window, the average incremental QALY benefit was 0.021.

113 Even assuming the lowest incremental QALYs for the most expensive moisturizer, the interventi

114 ate would result in 0.15 additional lifetime QALY, but this gain would cost an incremental $77 290, l

115 me cost was reduced by US $2090 and lifetime QALYs increased by 0.03.

116 low cost and a favorable cost-utility (low $/QALY) as a result of the minimization of the cost and mo

117 der than 55 years, ASGE guidelines maximized QALYs at the lowest cost.

118 The difference between the mean QALYs was 4.7 days (46.4 QALY days for the OSC plus WBRT

119 by $78 257), with patients accumulating more QALYs (by 0.42) than with the observed standard of care.

120 simulations resulted in lower costs and more QALYs.

121 d control was cost-saving and generated more QALYs compared with uniform intensive control, except in

122 first-line therapy provided marginally more QALYs but accumulated substantially higher drug costs.

123 increase in complications but produced more QALYs (16.68 vs. 16.58) due to fewer hypoglycemic events

124 improved on the old policy by producing more QALYs at lower cost.

125 IOC yielded more QALYs than EM in the base case (0.9854) but at a much hi

126 In the base case, SBRT-SBRT yielded the most QALYs (1.565) and cost $197 557.

127 Compared with NICE QALYs, correlation coefficients were 0.45 (ASCOv1), 0.53

128 analysis showed that the incremental gain of QALY ranged from 0.0041 to 0.030.

129 8,158 to -euro190) lower, and mean number of QALYs was 0.116 (95% CI, 0.005 to 0.227) higher in the i

130 y likely to be cost-effective; the number of QALYs was higher and cumulative costs were lower for SC

131 We determined that the mean number of QALYs would be 0.27 higher among patients who received i

132 , 0.53 (ASCOv2), and 0.46 (ESMO); with pCODR QALYs, coefficients were 0.19 (ASCOv1), 0.20 (ASCOv2), a

133 mpared with adding ezetimibe at $414,000 per QALY (80% UI, $277,000-$1,539,000).

134 0 simulations (for thresholds of $50 000 per QALY and $100 000 per QALY).

135 willingness-to-pay threshold of $50,000 per QALY and 76 to 93% below the threshold of $100,000 per Q

136 cost-effectiveness ratio of pound22 000 per QALY and a probability of cost-effectiveness of 20%.

137 event 316,300 MACE at a cost of $503,000 per QALY gained compared with adding ezetimibe to statins (8

138 ry 3 years would cost less than $100,000 per QALY gained if the MT-sDNA test achieved a participation

139 he potential to cost less than US$50,000 per QALY gained relative to the next best portfolio.

140 fectiveness threshold (about pound30 000 per QALY gained) after 33 years.

141 s strategies and a threshold of $100,000 per QALY gained, FIT was preferred in 99.3% of iterations in

142 willingness-to-pay threshold of $100 000 per QALY gained, RFA-SBRT was preferred in 65.8% of simulati

143 st-risk subgroup cost less than $100 000 per QALY gained.

144 eters caused the cost to exceed $100 000 per QALY gained.

145 ness at a willingness to pay of $100,000 per QALY gained.

146 ngness-to-pay (WTP) threshold of $50 000 per QALY gained.

147 However, under a pound30 000 per QALY threshold, the programme will remain cost-effective

148 36 would be necessary to meet a $100,000 per QALY threshold.

149 6 to 93% below the threshold of $100,000 per QALY), regardless of whether treatment effects were redu

150 esholds of $50 000 per QALY and $100 000 per QALY).

151 t-effectiveness threshold of pound15 000 per QALY, the low-risk elderly seasonal vaccination programm

152 willingness-to-pay threshold of $100,000 per QALY.

153 ERs otherwise remained less than $50,000 per QALY.

154 be cost-effective at less than $100,000 per QALY.

155 US$18,000 (95% CI: US$14,000, US$24,000) per QALY gained, 50% NSP coverage could avert up to 35,000 (

156 US$25,000 (95% CI: US$7,000, US$76,000) per QALY gained, 50% Test & Treat coverage could avert up to

157 US$27,000 (95% CI: US$15,000, US$48,000) per QALY gained, and 50% PrEP coverage could avert up to 37,

158 300,000 (95% CI: US$162,000, US$667,000) per QALY gained.

159 l cost-effectiveness ratios were $55,090 per QALY gained and $43,114 per LY gained.

160 cost-effectiveness threshold of $100000 per QALY compared with bevacizumab during a 10-year horizon;

161 willingness-to-pay threshold of $100000 per QALY was used to assess cost-effectiveness.

162 o 4 years, the ICER decreased to $114078 per QALY and became cost-effective by 5 years with an ICER o

163 Evolocumab treatment exceeded $150000 per QALY in most scenarios but would meet this threshold at

164 To achieve an ICER of $150000 per QALY, the annual net price would need to be substantiall

165 yielding an unfavorable ICER of $154684 per QALY.

166 y-adjusted life-year (QALY) and $1730000 per QALY, respectively.

167 eening scenarios were $19,600 to $29,200 per QALY, and the respective first-year prison budget was $9

168 CT screening every 5 years (ICER, $2000 per QALY).

169 er QALY in men and euro18687 (US $20044) per QALY in women for TBSE and euro34836 (US $37365) per QAL

170 er QALY in men and euro19470 (US $20884) per QALY in women for LDS.

171 ve blood pressure management cost $23777 per QALY gained.

172 was $18239 (95% CI, dominant to $24408) per QALY gained, with dominant indicating that the intervent

173 ntal QALY, 0.39, with an ICER of $268637 per QALY gained ($165689 with discounted price of $10311 bas

174 ICER) was euro6840.75 (95% CI 2545-2759) per QALY gained for a treatment efficacy of 20% and euro4243

175 b compared with bevacizumab were $287000 per QALY and $817000 per QALY, respectively.

176 at a cost-effectiveness ratio of $45 300 per QALY gained ($27 800-72 300).

177 cost-effectiveness ratio (ICER) of $323 per QALY, and naloxone distribution plus linkage to addictio

178 age to addiction treatment (ICER $95 337 per QALY) at a willingness-to-pay threshold of $100 000.

179 During 10 years, they were $349000 per QALY and $603000 per QALY, respectively.

180 -effectiveness ratio of ECHO was $10,351 per QALY compared with the status quo; >99.9% of iterations

181 tiveness ratios of euro33072 (US $35475) per QALY in men and euro18687 (US $20044) per QALY in women

182 women for TBSE and euro34836 (US $37365) per QALY in men and euro19470 (US $20884) per QALY in women

183 hold in Belgium of euro35000 (US $37541) per QALY gained.

184 hold in Belgium of euro35000 (US $37541) per QALY gained.

185 o $488642 per QALY, with ICER of $413579 per QALY for trial patient characteristics and event rate of

186 ost-effectiveness ratio (ICER) of $45017 per QALY for the base-case.

187 ed ICERs ranging from $100193 to $488642 per QALY, with ICER of $413579 per QALY for trial patient ch

188 rted, $645 per life-year saved, and $511 per QALY gained, compared with current practice.

189 $77 290, leading to an ICER of $521 520 per QALY per patient.

190 ctiveness ratio of pound5,786 (US$8,521) per QALY.

191 , they were $349000 per QALY and $603000 per QALY, respectively.

192 ed, or 0.62 QALYs, at a cost of $472,668 per QALY gained.

193 SBRT was not cost-effective, at $558 679 per QALY gained relative to RFA-SBRT.

194 % (95% UR, 13%-26%) at a cost of $65 700 per QALY gained ($44 500-111 000).

195 ffectiveness ratio (ICER) of pound10 726 per QALY.

196 ated ICERs ranging from $35357 to $75301 per QALY.

197 2,799 and 5.42 QALY, yielding US $63,775 per QALY gained.

198 izumab were $287000 per QALY and $817000 per QALY, respectively.

199 ective by 5 years with an ICER of $91032 per QALY.

200 CER) was presented as costs in Thai baht per QALY gained.

201 6 849, cost per line-year $575, and cost per QALY $19 150.

202 $7252, cost per line-year $240, and cost per QALY $7988.

203 entially cost-effective in terms of cost per QALY (incremental cost-effectiveness ratio, $70831-$1363

204 entially cost-effective in terms of cost per QALY (incremental cost-effectiveness ratio, $92446).

205 The lifetime incremental cost per QALY for noncontrast MR cholangiopancreatography was $10

206 The average cost per QALY gained by additional 9vHPV vaccination exceeded $10

207 ration of improved outcomes, with a cost per QALY gained of $120 623 if the duration was limited to t

208 in incremental costs, equating to a cost per QALY gained of $47 053.

209 The cost per QALY gained was $44 531 in patients with NYHA class II h

210 0.03 to 0.13), the mean incremental cost per QALY gained was pound12 087.

211 ent better resource use in terms of cost per QALY gained.

212 with each strategy, and incremental cost per QALY gained.

213 The cost per QALY saved was $255 to $638/QALY ($100-$239/QALY).

214 t both fall well below the accepted cost per QALY upper limit.

215 ion to lifetime therapy yielded the cost per QALY with PRP treatment of $14 219 to $24 005 and with I

216 of defined health states, QALY, and cost per QALY.

217 xceed the typical accepted limit of cost per QALY.

218 rs (QALYs), costs, and incremental costs per QALY gained.

219 ent and as ICER showing additional costs per QALY.

220 the no-test option (less than euro30000 per QALY).

221 a treatment efficacy of 20% and euro4243 per QALY gained for treatment efficacy of 50%.

222 ctiveness ratio (ICER), defined as euros per QALY.

223 ate and triple therapy were $2.7 million per QALY and $0.98 million per QALY over 24 and 48 weeks, re

224 $2.7 million per QALY and $0.98 million per QALY over 24 and 48 weeks, respectively.

225 cost would be approximately $28,000 more per QALY gained if the treatment effects persisted for the r

226 nd would cost approximately $47,000 more per QALY gained if there were a reduction in adherence and t

227 ]) and the 12-week programme ( pound3804 per QALY).

228 l cost-effectiveness ratio was pound5374 per QALY gain.

229 low common willingness-to-pay thresholds per QALY, regardless of whether benefits were reduced after

230 f S$173 per person) while generating similar QALYs compared with the physician-based model (i.e., 13.

231 treatment, utility of defined health states, QALY, and cost per QALY.

232 The QALYs were calculated using Child Depression Rating Scal

233 the incremental cost-effectiveness values ($/QALY) for each moisturizer in preventing atopic dermatit

234 time horizon, ticagrelor was associated with QALY gains of 0.078 and incremental costs of $7,435, yie

235 SMO-MCBS, as well as their correlations with QALYs and with NICE/pCODR funding recommendations, sugge

236 emental cost per quality-adjusted life year (QALY) and varied model inputs in one-way and probabilist

237 U.S. dollars per quality-adjusted life year (QALY) gained and number of fragility fractures.

238 emental cost per quality-adjusted life year (QALY) gained from each diagnostic strategy.

239 d of pound20 000/quality-adjusted life year (QALY).

240 ere $1110000 per quality-adjusted life-year (QALY) and $1730000 per QALY, respectively.

241 emental cost per quality-adjusted life-year (QALY) gained by additional 9vHPV vaccination was $146 20

242 and the cost per quality-adjusted life-year (QALY) gained, as well as the budget effect, expressed as

243 and the cost per quality-adjusted life-year (QALY) gained, as well as the budget effect, expressed as

244 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 207 (268 162-1 903 385) per death

245 ed; and cost per quality-adjusted life-year (QALY) gained.

246 of $100,000 per quality-adjusted life-year (QALY) gained.

247 g, mean cost per quality-adjusted life-year (QALY) of screening all admissions was pound89,000-148,00

248 Quality-adjusted-life-year (QALY) will be estimated taking an area under the curve a

249 emental cost per quality-adjusted life-year (QALY), and total effect on US health care spending over

250 ovascular death, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), and

251 ed as dollar per quality-adjusted life-year (QALY), were calculated with incremental cost-effectivene

252 ife-year and per quality-adjusted life-year (QALY).

253 R) was <$100 000/quality-adjusted life-year (QALY).

254 han $100 000 per quality-adjusted life-year [QALY] gained), while contrast-enhanced MR imaging was fa

255 ( pound2394 per quality-adjusted life-year [QALY]) and the 12-week programme ( pound3804 per QALY).

256 The additional quality adjusted life years (QALY) with intervention was 0.08 (95% CI 0.03 to 0.13),

257 ost of care and quality-adjusted life years (QALY).

258 sed to evaluate quality-adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER) o

259 red in cost per quality-adjusted life-years (QALY) gained.

260 fit in terms of quality-adjusted life years (QALYs) (0.0325, 95% CI -0.0074 to 0.0724), and on the co

261 ere measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER).

262 imate costs and quality-adjusted life years (QALYs) comparing between the combination of pegylated in

263 (2016 US$) and quality-adjusted life years (QALYs) for treatment sequences with first-line NIVO, IPI

264 t and number of quality-adjusted life years (QALYs) gained.

265 d as discounted quality-adjusted life years (QALYs), costs in U.S. dollars, and cost-effectiveness ex

266 Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios

267 es in survival, quality-adjusted life years (QALYs), costs, and resulting budget impact between ECHO

268 Quality-adjusted life years (QALYs), total cost, disease progression, and the probabi

269 erive costs and quality-adjusted life years (QALYs).

270 ative costs and quality-adjusted life years (QALYs).

271 res: Discounted quality-adjusted life-years (QALYs) and discounted costs.

272 they relate to quality-adjusted life-years (QALYs) and funding recommendations in the United Kingdom

273 e difference in quality-adjusted life-years (QALYs) between groups from baseline to 12 months.

274 uent costs, and quality-adjusted life-years (QALYs) for intensive control versus standard control of

275 Quality-adjusted life-years (QALYs) for use in cost-utility analysis were derived fro

276 ctive number of quality-adjusted life-years (QALYs) gained in the test and no-test option were 61 820

277 was measured as quality-adjusted life-years (QALYs) gained or lost by investing resources in a new st

278 ietal costs per quality-adjusted life-years (QALYs) gained.

279 emental gain in quality-adjusted life-years (QALYs) was determined using a 6-month time window.

280 In-trial quality-adjusted life-years (QALYs) were similar (2.28 vs. 2.27; p = 0.34).

281 HIV infections, quality-adjusted life-years (QALYs), and costs.

282 remental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs

283 rs), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.

284 d as discounted quality-adjusted life-years (QALYs), costs in US dollars, and cost effectiveness expr

285 spitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained.

286 es: Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospitalizations, and incre

287 fe-years (LYs), quality-adjusted life-years (QALYs), direct medical expenditure, and cost per LY and

288 etime costs and quality-adjusted life-years (QALYs), discounted at 3% annually.

289 expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results

290 ife expectancy, quality-adjusted life-years (QALYs), number and percentage of overdose deaths averted

291 Quality-adjusted life-years (QALYs), total costs (in US dollars adjusted to 2015-year

292 life-years, and quality-adjusted life-years (QALYs).

293 lity, costs and quality-adjusted life-years (QALYs).

294 care costs with quality-adjusted life-years (QALYs).

295 ome measure was quality-adjusted life-years (QALYs).

296 red in terms of quality-adjusted life-years (QALYs).

297 e gain of 0.32 quality-adjusted life-years ([QALY]; 0.41 LY) with 3% discounting.

298 and discounted quality-adjusted life years [QALYs]), and incremental cost-effectiveness ratios (ICER

299 .221 discounted quality-adjusted life-years [QALYs] per patient with monitoring every 24 to 1 month o

300 effectiveness (quality-adjusted life-years [QALYs]), and incremental cost-effectiveness ratios of va